ESWI held a very successful Roundtable on 15 September in Vienna, focusing on facilitating dialogue to improve influenza prevention, control and vaccine uptake.

As COVID-19 transitions from a pandemic to an endemic disease, its integration into the broader policy and healthcare framework for respiratory diseases becomes imperative.

This year, 15 October marks the evolution of #EUFluDay into #EURespiDay, a broader call for EU action on respiratory infection prevention.

With the contribution of the European Association of Preventive Cardiology (EAPC), the Association for Acute CardioVascular Care (ACVC), and the Heart Failure Association (HFA) of the ESC

Superior protection against laboratory-confirmed influenza has been proved for high-dose inactivated influenza vaccine, as compared with the standard dose, among adults 65 years of age or older.

The second edition of the Pandemic Influenza Severity Assessment (PISA) provides countries with a systematic framework to interpret surveillance data and communicate risks effectively.

The high morbidity and mortality emphasize the need for prevention, early recognition, intensive treatment, and standardized management protocols.

Influenza viruses pose a significant public health threat, causing seasonal epidemics and occasional pandemics with substantial morbidity and mortality worldwide.